Regulatory approval

Published by the Health Service Executive. Approved

Obinutuzumab in combination with CHOP chemotherapy is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Obinutuzumab - ODMS 2019-05-01; cyclophosphamide, doxorubicin, and vincristine - N/A

Citation

Obinutuzumab, cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (O-CHOP) Therapy - 21 day, 2026, version number 3, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/8393/549_Obinutuzumab-CHOP.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	CD20 +	Follicular Lymphoma	Cyclophosphamide, Doxorubicin, Obinutuzumab, Prednisolone, Vincristine

Contributions

Date	Contributor	Description
2026-08-02	Van Allen lab	Initial curation of into moalmanac-db
2019-05-01	Health Service Executive	Indication approved for reimbursement.